Page last updated: 2024-11-09

srpin340

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2797577
CHEMBL ID4064277
SCHEMBL ID1110476
MeSH IDM0588561

Synonyms (40)

Synonym
SR-01000634086-1
HMS1661E15
n-[2-piperidin-1-yl-5-(trifluoromethyl)phenyl]pyridine-4-carboxamide
bdbm50235034
chembl4064277 ,
CCG-44237
srpin340
n-[2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl]pyridine-4-carboxamide
n-[2-(1-piperidyl)-5-(trifluoromethyl)phenyl]pyridine-4-carboxamide
S7270 ,
n-[2-(1-piperidinyl)-5-(trifluoromethyl) phenyl]isonicotinamide
n-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide
FD5022
218156-96-8
srpin 340
CS-1681
HY-13949
mfcd00116244
SCHEMBL1110476
AKOS024262286
3ul ,
n-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
4-pyridinecarboxamide, n-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]-
n-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide
AC-32641
EX-A208
srpk inhibitor
HMS3653I06
Z26785878
srpin340, >=98% (hplc)
J-014302
NCGC00370995-10
SW219726-1
FT-0700266
BCP08400
AS-16588
Q27454157
EN300-160203
sr protein phosphorylation inhibitor 340
n-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.00810.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency2.13170.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency8.48660.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency2.13170.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.13170.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.13170.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.13170.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SRSF protein kinase 1Mus musculus (house mouse)Ki0.89000.89000.89000.8900AID1436443
SRSF protein kinase 2Homo sapiens (human)IC50 (µMol)7.40000.18502.60407.4000AID1851165
SRSF protein kinase 1Homo sapiens (human)IC50 (µMol)0.89000.02450.28810.8900AID1851164
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 2Homo sapiens (human)
angiogenesisSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSRSF protein kinase 2Homo sapiens (human)
RNA splicingSRSF protein kinase 2Homo sapiens (human)
positive regulation of gene expressionSRSF protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 2Homo sapiens (human)
cell differentiationSRSF protein kinase 2Homo sapiens (human)
nuclear speck organizationSRSF protein kinase 2Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 2Homo sapiens (human)
positive regulation of neuron apoptotic processSRSF protein kinase 2Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
innate immune responseSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell cycleSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 2Homo sapiens (human)
R-loop processingSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
protein phosphorylationSRSF protein kinase 1Homo sapiens (human)
chromosome segregationSRSF protein kinase 1Homo sapiens (human)
RNA splicingSRSF protein kinase 1Homo sapiens (human)
sperm DNA condensationSRSF protein kinase 1Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 1Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
innate immune responseSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 1Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
protein serine kinase activitySRSF protein kinase 1Mus musculus (house mouse)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
magnesium ion bindingSRSF protein kinase 2Homo sapiens (human)
RNA bindingSRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein bindingSRSF protein kinase 2Homo sapiens (human)
ATP bindingSRSF protein kinase 2Homo sapiens (human)
14-3-3 protein bindingSRSF protein kinase 2Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
magnesium ion bindingSRSF protein kinase 1Homo sapiens (human)
RNA bindingSRSF protein kinase 1Homo sapiens (human)
protein kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein bindingSRSF protein kinase 1Homo sapiens (human)
ATP bindingSRSF protein kinase 1Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nucleoplasmSRSF protein kinase 1Mus musculus (house mouse)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
nucleoplasmSRSF protein kinase 2Homo sapiens (human)
nucleolusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolSRSF protein kinase 2Homo sapiens (human)
nuclear speckSRSF protein kinase 2Homo sapiens (human)
chromatinSRSF protein kinase 2Homo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
nucleoplasmSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
endoplasmic reticulumSRSF protein kinase 1Homo sapiens (human)
cytosolSRSF protein kinase 1Homo sapiens (human)
plasma membraneSRSF protein kinase 1Homo sapiens (human)
nuclear matrixSRSF protein kinase 1Homo sapiens (human)
nuclear speckSRSF protein kinase 1Homo sapiens (human)
chromatinSRSF protein kinase 1Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1466242Inhibition of SRPK in human NALM6 cells assessed as decrease in RON mRNA expression level at 20 uM after 24 hrs by qRT-PCR analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1466236Inhibition of SRPK in human NALM6 cells assessed as decrease in VEGF mRNA expression level at 20 uM after 24 hrs by qRT-PCR analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1440712Inhibition of GST-tagged SRPK1 (unknown origin) at 5 uM using GST-LBRNt (62 to 92 residues) as substrate by SDS-PAGE based autoradiography2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Lynamicin D an antimicrobial natural product affects splicing by inducing the expression of SR protein kinase 1.
AID1436443Inhibition of mouse His6-tagged SRPK1 expressed in Escherichia coli(BL21)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.
AID1466234Inhibition of SRPK in human NALM6 cells assessed as decrease in MAP2K1 mRNA expression level at 20 uM after 24 hrs by qRT-PCR analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1466214Cytotoxicity against human HL60 cells assessed as reduction in cell viability up to 200 uM after 48 hrs by MTT assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1466215Cytotoxicity against human Jurkat cells assessed as reduction in cell viability up to 200 uM after 48 hrs by MTT assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1466235Inhibition of SRPK in human NALM6 cells assessed as decrease in MAP2K2 mRNA expression level at 20 uM after 24 hrs by qRT-PCR analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1851165Inhibition of SRPK2 (unknown origin) incubated for 10 mins in presence of ATP by Kinase-Glo assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
AID1466216Cytotoxicity against human NALM6 cells assessed as reduction in cell viability up to 200 uM after 48 hrs by MTT assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1851164Inhibition of SRPK1 (unknown origin) using SRSF1 Arg-Ser (RS) peptide (NH2-RSPSYGRSRSRSRSRSRSRSRSNSRSRSY-OH) as substrate incubated for 10 mins in presence of ATP by Kinase-Glo assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
AID1466237Inhibition of SRPK in human NALM6 cell lysates assessed as reduction in phospho-SR epitopes signal at 20 uM after 24 hrs by Western blot analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (61.90)24.3611
2020's8 (38.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.49 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index6.00 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]